Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu, 610041, China.
Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
Front Med. 2021 Aug;15(4):528-540. doi: 10.1007/s11684-020-0798-1. Epub 2021 Jan 29.
Major depressive disorder (MDD) causes great decrements in health and quality of life with increments in healthcare costs, but the causes and pathogenesis of depression remain largely unknown, which greatly prevent its early detection and effective treatment. With the advancement of neuroimaging approaches, numerous functional and structural alterations in the brain have been detected in MDD and more recently attempts have been made to apply these findings to clinical practice. In this review, we provide an updated summary of the progress in translational application of psychoradiological findings in MDD with a specified focus on potential clinical usage. The foreseeable clinical applications for different MRI modalities were introduced according to their role in disorder classification, subtyping, and prediction. While evidence of cerebral structural and functional changes associated with MDD classification and subtyping was heterogeneous and/or sparse, the ACC and hippocampus have been consistently suggested to be important biomarkers in predicting treatment selection and treatment response. These findings underlined the potential utility of brain biomarkers for clinical practice.
重度抑郁症(MDD)会导致健康和生活质量大幅下降,增加医疗保健成本,但抑郁症的病因和发病机制在很大程度上仍不清楚,这极大地阻碍了其早期发现和有效治疗。随着神经影像学方法的进步,在 MDD 中已经检测到许多大脑的功能和结构改变,最近还尝试将这些发现应用于临床实践。在这篇综述中,我们提供了 MDD 心理影像学研究转化应用进展的最新总结,特别关注其潜在的临床应用。根据不同 MRI 模式在疾病分类、亚型和预测中的作用,介绍了不同 MRI 模式的可预见的临床应用。虽然与 MDD 分类和亚型相关的大脑结构和功能变化的证据存在异质性和/或稀疏性,但 ACC 和海马体一直被认为是预测治疗选择和治疗反应的重要生物标志物。这些发现强调了脑生物标志物在临床实践中的潜在应用价值。